הזדמנות עסקית זאת היא בת למעלה מחצי שנה
מומלץ לבדוק האם היא עדיין בתוקף
Our company was founded in Oct., 2005 and listed on Emerging Market in Taiwan Stock Exchange, has has extensive RandD experience, with former researchers worked at Medical and Pharmaceutical Industry Technology and Development Center, one of the most important pharmaceutical technology developing organizations in Taiwan. The company focuses on the development and commercialization of treatment covering oncology, immunology and specialty. We intend to use internally developed drug delivery technology platforms, such as OralPAS®, to improve the safety and efficacy of existing drugs and provide better medical choices in the specific therapeutic areas. We developed the selecting generic drugs and have received 4 drug certificates from Taiwan FDA, in-eluded Imipenem(Bestnem) and Gadopentetate(Gadomni) in 2007 and Cyclosporine(lmmurin) and Gadodiamide(Gadoscan) in 2009. Cyclosporine(lmmurin) is the first generic drug successfully developed by OralPAS® platform. We licensed in new drug-Bendamustine(lnnomustine) from Symbio in 2008 and receive new drug approval from TFDAin 2011 aftera bridge clinical study in Taiwan. Most of the developed new drugs and generic drugs, such as Gemcitabine oral, C08001(for hypertension disease CR form), Cyclosporine and C07001(for Pakison disease) filed patents globally and also received the patent approvals in manycountries included US, Europe and China etc.. Our Taiwan based company, with strong formulation development techniques and unique global part-nership strategy, commit to deliver superior products and meet global quality standards to fulfill patients' needs.